Edwards Lifesciences Corp. Price Target Increased to $75.00 by Analysts at RBC Capital (EW)
Analysts at RBC Capital increased their target price on shares of Edwards Lifesciences Corp. (NYSE:EW) from $72.00 to $75.00 in a research report issued to clients and investors on Tuesday, StockRatingsNetwork reports. The firm currently has a “sector perform” rating on the stock. RBC Capital’s price objective points to a potential upside of 4.01% from the company’s current price.
A number of other firms have also recently commented on EW. Analysts at Zacks upgraded shares of Edwards Lifesciences Corp. (NYSE:EW) from an “underperform” rating to a “neutral” rating in a research note to investors on Thursday, August 29th. They now have a $74.00 price target on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Edwards Lifesciences Corp. (NYSE:EW) from $85.00 to $90.00 in a research note to investors on Thursday, August 22nd. They now have a “buy” rating on the stock. Finally, analysts at Northland Capital Partners upgraded shares of Edwards Lifesciences Corp. (NYSE:EW) from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday, July 18th. They now have a $74.00 price target on the stock.
One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $80.69.
Edwards Lifesciences Corp. (NYSE:EW) traded up 0.54% during mid-day trading on Tuesday, hitting $72.11. The stock had a trading volume of 593,443 shares. Edwards Lifesciences Corp. has a 1-year low of $62.34 and a 1-year high of $110.79. The stock’s 50-day moving average is $71.50 and its 200-day moving average is $73.21. The company has a market cap of $8.096 billion and a price-to-earnings ratio of 20.96.
Edwards Lifesciences Corp. (NYSE:EW) last released its earnings data on Thursday, July 25th. The company reported $0.82 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.76 by $0.06. The company had revenue of $517.20 million for the quarter, compared to the consensus estimate of $514.59 million. During the same quarter in the prior year, the company posted $0.57 earnings per share. The company’s quarterly revenue was up 7.3% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp. will post $3.07 earnings per share for the current fiscal year.
In other Edwards Lifesciences Corp. news, VP Huimin Wang sold 4,850 shares of Edwards Lifesciences Corp. stock on the open market in a transaction dated Thursday, September 5th. The shares were sold at an average price of $71.24, for a total transaction of $345,514.00. Following the completion of the transaction, the vice president now directly owns 31,337 shares in the company. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.